- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer Center
NCI CANCERLIT® Search: Therapy of Acute Lymphocytic Leukemia - February 2002
National Cancer Institute®
Last Modified: February 1, 2002
Table of Contents
1
UI - 11808492
AU - Cakesen H; Oner AF
TI -
Toxic epidermal necrolysis in a girl with leukemia receiving
methotrexate.
SO - Indian Pediatr 2001 Apr;38(4):426
2
UI - 11697630
AU - Watanabe J; Kondo H; Hatake K
TI -
Autologous stem cell transplantations for recurrent adult T cell
leukaemia/lymphoma using highly purified CD34+ cells derived from
cryopreserved peripheral blood stem cells.
SO - Leuk Lymphoma 2001 Sep-Oct;42(5):1115-7
AD - Division of Clinical Chemotherapy, Cancer Chemotherapy Centre, Japanese
Foundation for Cancer Research, Tokyo. jwatanabe@jfcr.or.jp
We performed double autologous PBSCT in one fulminantly relapsed ATL
patient. Cryopreserved PBSCs containing tumour cells were thawed, and
CD34+ cells were selected for by immunomagnetic beads, with the aim of
decreasing the number of re-infused tumour cells. The patient received
0.72x10(6) and 0.90x10(6) CD34+ cells/kg. The graft contained less than
0.1% T cells. The patient had a very good recovery, and maintained a
good quality of life, until she died on Day 339 after her first PBSCT in
third relapse. We conclude that autologous PBSCT for ATL patient has
benefit in some instances, and cryopreserved PBSCs can be used for CD34+
selection.
3
UI - 11813173
AU - Little MA; Morland B; Chisholm J; Hole A; Shankar A; Devine T; Easlea D;
TI -
Meyer LC; Pinkerton CR
A randomised study of prophylactic G-CSF following MRC UKALL XI
intensification regimen in childhood ALL and T-NHL.
SO - Med Pediatr Oncol 2002 Feb;38(2):98-103
AD - Royal Marsden Hospital, Sutton, United Kingdom.
BACKGROUND: Despite the current widespread use of prophylactic G-CSF in
children with solid tumours and leukaemia, its effectiveness has not
been clearly demonstrated. This randomised study evaluates the role of
G-CSF given after a 5-day intensification block in children with acute
lymphoblastic leukaemia (ALL). PROCEDURE: Forty-six children with ALL or
T-Cell non-Hodgkins lymphoma (NHL) treated on MRC ALL 97, UKALL XI or
UKCCSG 9504 NHL protocols were randomised to receive granulocyte
colony-stimulating factor following either the first or the second block
of intensive chemotherapy in a cross-over study to determine if the
prophylactic administration of G-CSF could reduce the rate of
readmission to hospital for management of febrile neutropenia. RESULTS:
There was a statistically significant difference in the rate of hospital
admission in the group receiving prophylaxis, with 34 of 46 being
admitted, compared to 42 of 46 patients in the control arm (74 vs. 91%;
P=0.0386). There were no differences found in duration of hospital
admission, haematological toxicity, neutrophil recovery or duration of
supportive care between the two groups. There was no demonstrable cost
benefit derived from the prophylactic administration of G-CSF.
CONCLUSIONS: This study shows that the prophylactic administration of
G-CSF following intensification chemotherapy for childhood ALL and T-NHL
produces a significant reduction in the rate of readmission to hospital
for the management of febrile neutropenia. Copyright 2002 Wiley-Liss,
Inc.
4
UI - 11734299
AU - Kishino K; Muroi K; Kawano C; Obata T; Sugano N; Nakagi Y; Nagashima T;
TI -
Watari K; Iwamoto S; Ozawa K
Evaluation of engraftment by ABO genotypic analysis of erythroid
burst-forming units after bone marrow transplantation.
SO - Leuk Res 2002 Jan;26(1):13-7
AD - Division of Cell Transplantation and Transfusion, Jichi Medical School,
Minamikawachi, 329-0498, Tochigi, Japan.
Six patients received an allogeneic bone marrow transplant from
HLA-identical ABO-mismatched donors. ABO genotype of erythroid
burst-forming units (BFU-E) from peripheral blood was analyzed using
polymerase chain reaction with sequence specific primers (PCR-SSP).
After bone marrow transplantation (BMT), engraftment of donor cells by
ABO genotypic analysis of BFU-E was compared with ABO phenotypic
analysis of red blood cells (RBCs). During the early stage after BMT,
ABO genotype of BFU-E in the recipients converted to that of the donors.
In contrast, mixed ABO phenotype of RBCs persisted for about 3 months.
In one patient, autologous hemopoietic cell recovery was detected by the
ABO genotypic analysis before clinical manifestation. ABO genotypic
analysis of BFU-E is relevant for enagraftment after ABO-mismatched BMT.
5
UI - 11426550
AU - White JD; Wharfe G; Stewart DM; Maher VE; Eicher D; Herring B; Derby M;
TI -
Jackson-Booth PG; Marshall M; Lucy D; Jain A; Cranston B; Hanchard B;
Lee CC; Top LE; Fleisher TA; Nelson DL; Waldmann TA
The combination of zidovudine and interferon alpha-2B in the treatment
of adult T-cell leukemia/lymphoma.
SO - Leuk Lymphoma 2001 Jan;40(3-4):287-94
AD - Metabolism Branch, National Cancer Institute, University of the West
Indies, Kingston, Jamaica.
Adult T-cell leukemia/lymphoma (ATL) is frequently a very aggressive
malignancy with a poor survival despite aggressive multiagent
chemotherapy. The combination of the antiretroviral drug zidovudine
(AZT) and interferon alpha (IFNalpha) has been reported to induce
remissions in patients with ATL. The purpose of this study was to
evaluate the clinical response and toxicity following administration of
a combination of IFNalpha-2b and AZT in patients with human T-cell
lymphotropic virus type I (HTLV-I)-associated ATL. Eighteen patients
with ATL (chronic. crisis, acute or lymphoma type) were treated with the
combination of AZT (50 - 200 mg orally 5 times a day) and IFNalpha-2b
(2.5 - 10 million units subcutaneously daily). Three patients had
objective responses lasting more than one month. One patient had a
clinical complete remission, lasting 21.6 months and two patients had
partial remissions lasting 3.7 and 26.5 months. Six patients were not
considered evaluable for response due to short and/or interrupted
periods of treatment. Seventeen patients have died with a median
survival time after initiation of therapy of 6 months. Neutropenia and
thrombocytopenia were the dose limiting toxicities. In conclusion, the
response rate in this study was lower than noted in the two previous
published series. This may be due to the amount and type of prior
treatment our patients had received.
6
UI - 11680836
AU - Castagnola E; Zarri D; Caprino D; Losurdo G; Micalizzi C
TI -
Cotrimoxazole prophylaxis of Pneumocystis carinii infection during the
treatment of childhood acute lymphoblastic leukemia--beware non
compliance in older children and adolescents.
SO - Support Care Cancer 2001 Oct;9(7):552-3
AD - Infectious Diseases Unit, G. Gaslini Children's Hospital, Genova, Italy.
eliocastagnola@ospedale-gaslini.ge.it
7
UI - 11780471
AU - Ma Y; Li Z; Chen G; Dong P; Jiang Y; Zeng Y
TI -
Short-term complete remission of a patient with human T lymphotropic
virus type-1 associated adult T-cell leukemia/lymphoma with pancytopenia
by sequential high-dose methylprednisolone and cyclosporin A.
SO - Chin Med J (Engl) 2001 Apr;114(4):428-30
AD - Department of Hematology, China-Japan Friendship Hospital, Beijing
100029, China.
8
UI - 11835241
AU - Shimokawa T; Ohashi H; Takaue Y; Kawano Y; Abe T; Kuroda Y
TI -
Successful umbilical cord blood transplantation in an infant with ALL
failing initial autologous peripheral blood stem cell transplantation.
SO - Med Pediatr Oncol 2002 Jan;38(1):60-1
AD - Department of Pediatrics, National Shikoku Cancer Center Hospital,
Matsuyama, Japan. tshimoka@shikoku-cc.go.jp
9
UI - 11835247
AU - Willert JR; Dahl GV; Marina NM
TI -
Recurrent mercaptopurine-induced acute pancreatitis: a rare complication
of chemotherapy for acute lymphoblastic leukemia in children.
SO - Med Pediatr Oncol 2002 Jan;38(1):73-4
10
UI - 11838420
AU - Agger KE; Schroder H; Rosthoj S; Carlsen NT; Schmiegelow K
TI -
[Trimethoprim-sulfamethoxazole as antibacterial prophylaxis during
induction therapy of children with acute lymphatic leukemia]
SO - Ugeskr Laeger 2002 Jan 21;164(4):488-92
AD - Arhus Universitetshospital, Skejby Sygehus, borneonkologisk afdeling,
DK-8200 Arhus N.
INTRODUCTION: Children with acute lymphoblastic leukaemia (ALL) are
treated with intensive chemotherapy, which results in profound
immunosuppression. Treatment with trimethoprim/sulphamethoxazole
(TMP-SMX) is therefore used in some departments as prophylaxis against
infections with both bacteria and Pneumocystis carinii. The use of
TMP/SMX for prophylaxis during the induction therapy is not uniform in
the four departments of paediatric oncology in Denmark. This gave us the
opportunity to describe the effect of TMP/SMX on bacterial infections in
children with ALL during the induction therapy. MATERIAL AND METHODS:
with ALL in Denmark. From a retrospective review of the medical charts,
the number of children with fever (> 38 degrees C), the number of
febrile days, days of antibiotic treatment, and the number of positive
blood cultures were registered for each febrile episode. RESULTS: One
hundred and fourteen children received TMP/SMX prophylaxis (10-30
mg/SMX/kg/day) and 76 did not. Children who received TMP/SMX prophylaxis
had significantly fewer episodes of fever (66/114 (58%) vs. 60/76 (79%),
p < 0.01) and significantly fewer children who received the prophylaxis
had positive blood cultures before the start of antibiotic treatment
compared with children who did not receive prophylaxis (23/114 (20%) vs
37/76 (49%), p < 0.001)). Nineteen different species were isolated from
the blood stream before the start of antibiotic treatment. In the
non-prophylaxis group there were a preponderance of isolates with Staph.
aureus, Str. pneumoniae, E. coli, and P. aeruginosa. There was no
difference in the mortality between the two groups (p = 0.44). There
were no cases of P. carinii pneumonia in the period of induction
therapy. DISCUSSION: TMP/SMX prophylaxis during induction therapy for
childhood ALL seems to reduce the risk of bacteraemias and febrile
illness.
11
UI - 11783498
AU - De Abreu RA; Lambooy LH; Ahment K; Brouwer C; Keizer-Garritsen JJ;
TI -
Bokkerink JP; Trijbels FJ
6-mercaptopurine: efficacy and bone marrow toxicity in childhood acute
lymphoblastic leukemia. Association with low (thio)purine enzyme
activity.
SO - Adv Exp Med Biol 2000;486():271-5
AD - Department of Pediatrics, Center for Pediatric Oncology SEN, University
Medical Center St Radboud, Nijmegen, The Netherlands.
12
UI - 11781621
AU - Schneider M; Hettinger K; Matthes-Martin S; Konrad M; Peters C; Gadner
TI -
H; Panzer-Grumayer ER
Influence of transplantation regimen on prognostic significance of
high-level minimal residual disease before allogeneic stem cell
transplantation in children with ALL.
SO - Bone Marrow Transplant 2001 Dec;28(11):1087-9
AD - Children's Cancer Research Institute and St Anna Kinderspital, Vienna,
Austria.
High MRD levels before transplantation in children receiving T
cell-depleted unrelated grafts for relapsed ALL were associated with a
100% relapse risk. We report on two children with relapsed ALL who
underwent non T cell-depleted BMT from unrelated donors. Despite a high
residual tumor load pre- transplant and the occurrence of only aGVHD
grade I, they are still in second complete remission 2.7 and 5.2 years
after transplantation, respectively. Thus, we propose that the
transplant regimens influence the prognostic significance of high MRD
levels pre-BMT.
13
UI - 11853786
AU - Griffin JD
TI -
Resistance to targeted therapy in leukaemia.
SO - Lancet 2002 Feb 9;359(9305):458-9
AD - Leukemia Program, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
james_griffin@dfci.harvard.edu
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
